SLC5A2 and type 2 diabetes mellitus: Here, we conducted a multicenter, randomized trial to compare the effects of a SGLT2 inhibitor (ipragliflozin) and a DPP4 inhibitor (sitagliptin) in patients with type 2 diabetes.